Literature DB >> 34560310

American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation.

Michelle K Yong1, Terri Lynn Shigle2, Yae-Jean Kim3, Paul A Carpenter4, Roy F Chemaly5, Genovefa A Papanicolaou6.   

Abstract

The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) partnered with its Transpl. Infect. Dis. Special Interest Group (TID-SIG) to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A new approach was employed with the goal of better serving clinical providers by publishing each standalone topic in the infectious diseases series as a concise format of frequently asked questions (FAQ), tables, and figures. Adult and pediatric infectious diseases and HCT content experts developed and answered FAQs. Topics were finalized with harmonized recommendations that were made by assigning an A through E strength of recommendation paired with a level of supporting evidence graded I through III. The fourth topic in the series focuses on the management and treatment of cytomegalovirus (CMV) resistant and refractory infections. The diagnosis, definitions of resistant and refractory CMV, risk factors, virological genotypes and treatment algorithms are reviewed. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2021        PMID: 34560310     DOI: 10.1016/j.jtct.2021.09.010

Source DB:  PubMed          Journal:  Transplant Cell Ther        ISSN: 2666-6367


  1 in total

1.  Donor-derived cytomegalovirus-cytotoxic T lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: A case report.

Authors:  Nan Su; Zhenghua Liu; Peng Sun; Feng Gu; Xiaojing Yan; Dali Cai
Journal:  Front Med (Lausanne)       Date:  2022-09-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.